MET amplifications have been found in a number of tumor types including glioblastoma (GBM) [9, 10] and missense mutations in the Sema, the TK and the JM domain have been reported to affect HGF binding, kinase activation and receptor degradation, respectively [1, 30, 32, 36, 38, 43, 48, 49]. Here, MET is linked to glioblastoma.